Market research
BV3.F Bavarian Nordic A/S
F EUR Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- P/E ratio
- 13.14
- Analyst target
- 57.15
- Dividend yield
- Not available
- Beta
- 0.97
Profile
Instrument facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- DK0015998017
- P/E ratio
- 13.14
- Analyst target
- 57.15
- Dividend yield
- Not available
- Beta
- 0.97
About
About Bavarian Nordic A/S
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Research context
Bavarian Nordic A/S appears in PyInvesting’s Frankfurt Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BV3.F discussion.
5 years, 7 months ago
Bavarian Nordic A/S is currently in a long term uptrend where the price is trading 10.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 8.3.
Bavarian Nordic A/S's total revenue sank by 21.1% to $229M since the same quarter in the previous year.
Its net income has dropped by 716.5% to $-375M since the same quarter in the previous year.
Finally, its free cash flow grew by 62.1% to $-901M since the same quarter in the previous year.
Based on the above factors, Bavarian Nordic A/S gets an overall score of 3/5.